Clinical Trial Update: A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen [Phase 1]

View source ↗

Summary

Phase 1 study of a mixed bacteria vaccine (MBV) targeting NY-ESO-1 tissue expression in various tumors; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Gastrointestinal Stromal Tumor
• Head and Neck Cancer
• Melanoma
• Ovarian Carcinoma
• Prostate Cancer
• Sarcoma
• Transitional Cell Carcinoma

Drugs mentioned

• Mixed Bacteria Vaccine (MBV)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Melanoma, Sarcoma | Phase 1 | Status: COMPLETED | Results posted: 2017-01-09